Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | MLH1 negative |
Therapy | Nivolumab |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MLH1 negative | Advanced Solid Tumor | predicted - sensitive | Nivolumab | Phase II | Actionable | In a Phase II trial (NCI-MATCH), Opdivo (nivolumab) treatment demonstrated preliminary efficacy in advanced solid tumor patients (excluding colorectal cancer) with deficient mismatch repair (defined by the loss of MLH1 or MSH2 expression by IHC), resulting in an objective response rate of 36% (15/42, 3 complete and 12 partial responses), a median progression-free survival (PFS) of 6.3 mo, a 6-month PFS rate of 51.3%, and a median overall survival of 17.3 months (PMID: 31765263; NCT02465060). | 31765263 |
PubMed Id | Reference Title | Details |
---|---|---|
(31765263) | Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. | Full reference... |